Literature DB >> 20689340

Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.

Thomas A Mavrakanas1, Angeliki Cheva, Konstantinos Kallaras, Georgios Karkavelas, Maria Mironidou-Tzouveleki.   

Abstract

BACKGROUND/AIMS: We studied the effect of the combined treatment with an angiotensin-converting enzyme (ACE) inhibitor (ramipril) and eplerenone compared with ramipril alone in streptozocin-induced diabetic rats.
METHODS: Wistar rats were divided into 4 groups: nondiabetic controls, streptozocin-treated diabetic rats (50 mg/kg), diabetic rats receiving ramipril (1 mg/kg) and diabetic rats treated with the combination of ramipril (1 mg/kg) and eplerenone (100 mg/kg) for 8 weeks. Our model produced early-stage diabetic nephropathy.
RESULTS: The diabetic rats developed polyuria, proteinuria, hyperfiltration (assessed by creatinine clearance) and histopathological evidence of renal injury including glomerular hypertrophy and mesangial expansion. Ramipril reduced proteinuria but its combination with eplerenone did not produce any greater benefit. Both treatment approaches prevented glomerular hypertrophy. Addition of eplerenone to ramipril prevented glomerular hyperfiltration.
CONCLUSION: Whether eplerenone should be used in addition to an ACE inhibitor or an angiotensin receptor blocker at an early stage of diabetic nephropathy remains questionable. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689340     DOI: 10.1159/000316113

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  1 in total

1.  Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats.

Authors:  Jae Hee Ahn; Ho Cheol Hong; Myong Jin Cho; Yoon Jung Kim; Hae Yoon Choi; Chai Ryoung Eun; Sae Jeong Yang; Hye Jin Yoo; Hee Young Kim; Ji A Seo; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Dong Seop Choi; Nan Hee Kim
Journal:  Diabetes Metab J       Date:  2012-04-17       Impact factor: 5.376

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.